The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.

ABSTRACT: Autologous haematopoietic stem cell transplantation (aHSCT) is gaining traction as a valuable treatment option for patients affected by severe multiple sclerosis (MS), particularly the relapsing-remitting form. We describe the current literature in terms of clinical trials, observational and retrospective studies, as well as immune reconstitution following transplantation, with a focus on the conditioning regimens used for transplantation. The evidence base predominantly consists of non-randomised, uncontrolled clinical trials or data from retrospective or observational cohorts, i.e. very few randomised or controlled trials. Most often, intermediate-intensity conditioning regimens are used, with promising results from both myeloablative and lymphoablative strategies, as well as from regime

SUBMITTER: Willison AG 

PROVIDER: S-EPMC8995166 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature